OZ439/DSM265联合治疗无并发症恶性疟的最优给药方案探索
本研究利用生物学导向的宿主体内数学模型,分析四项健康志愿者感染恶性疟试验数据,评估OZ439与DSM265联合疗效。模型预测800 mg OZ439联合450 mg DSM265在安全耐受剂量范围内,给药后42天治愈率可超90%,提示该组合有望替代青蒿素联合疗法。
要点
- OZ439 800 mg联合DSM265 450 mg预测42天治愈率超90%。
- 该剂量在安全耐受范围内,支持后续临床试验。
- 模型可指导OZ439/DSM265的2/3期试验设计。
核心结论
- OZ439与DSM265联合有望成为替代ACTs的候选方案。
- 模型预测800 mg OZ439联合450 mg DSM265的42天治愈率超90%。
研究设计与样本
- 基于宿主体内数学模型,分析四项健康志愿者感染恶性疟试验数据。
- 三项试验单用OZ439或DSM265,第四项为两者联合。
- 参数在分层贝叶斯框架下估计。
主要发现
- 模型后验预测模拟显示800 mg OZ439联合450 mg DSM265给药后42天治愈率超90%。
- 该剂量在安全耐受剂量范围内。
关键数值与推荐
- 800 mg OZ439联合450 mg DSM265预测42天治愈率>90%。
临床怎么用
- 该模型可 informing 未来OZ439/DSM265的2期和3期临床试验。
- 建议在ACTs失败地区加速部署该联合疗法。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The efficacy of artemisinin-based combination therapies (ACTs), the first-line treatments for uncomplicated falciparum malaria, has been declining in malaria-endemic countries due to the emergence of malaria parasites resistant to these compounds. Novel alternative therapies are needed urgently to prevent the likely surge in morbidity and mortality due to failing ACTs. OBJECTIVES: This study investigates the efficacy of the combination of two novel drugs, OZ439 and DSM265, using a biologically informed within-host mathematical model. METHODS: A within-host model was developed, which accounts for the differential killing of these compounds against different stages of the parasite's life cycle and accommodates the pharmacodynamic interaction between the drugs. Data of healthy volunteers infected with falciparum malaria collected from four trials (three that administered OZ439 and DSM265 alone, and the fourth a combination of OZ439 and DSM265) were analysed. Model parameters were estimated in a hierarchical Bayesian framework. RESULTS: The posterior predictive simulations of our model predicted that 800 mg of OZ439 combined with 450 mg of DSM265, which are within the safe and tolerable dose range, can provide above 90% cure rates 42 days after drug administration. CONCLUSIONS: Our results show that the combination of OZ439 and DSM265 can be a promising alternative to replace ACTs. Our model can be used to inform future Phase 2 and 3 clinical trials of OZ439/DSM265, fast-tracking the deployment of this combination therapy in the regions where ACTs are failing. The dosing regimens that are shown to be efficacious and within safe and tolerable limits are suggested for future investigations.
引用
- Dini S, Zaloumis SG, Price DJ, et al. Seeking an optimal dosing regimen for OZ439/DSM265 combination therapy for treating uncomplicated falciparum malaria. J Antimicrob Chemother. 2021. PMID: 34179977. doi:10.1093/jac/dkab181
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。